Investors would be forgiven if talk of a potential suicide risk associated with a new class of diabetes and weight loss drugs led to skittishness last week. Prior attempts to treat overweight or obese patients with medications were often plagued with side effects and drug recalls. Those earlier medications often didn't seem like the results were worth the risks.
Still, Anderson said there are good reasons to believe this is "very likely not a major concern," including the clinical profile of GLP-1 medications, which have been around since 2005 as diabetes treatments. Also, any comparison with Acomplia should note that the concerns about that drug's connection to depression and anxiety were observed very early on during its clinical trials. This was not the case for the GLP-1 medications.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: FXStreetNews - 🏆 14. / 72 Read more »
Source: therealautoblog - 🏆 528. / 51 Read more »
Source: CoinDesk - 🏆 291. / 63 Read more »
Source: RollingStone - 🏆 483. / 51 Read more »
Stocks are on fire as investors pile in amid falling inflationRisky assets like stocks are on fire as investors pile into the market amid tumbling inflation, Bank of America says
Source: BusinessInsider - 🏆 729. / 51 Read more »
Investors are chasing the most speculative names in the stock marketInvestors are once again chasing some of the most speculative names in the stock market
Source: BusinessInsider - 🏆 729. / 51 Read more »